Drugs with expired main patents
1. List of Abilify drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(8 months ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(8 months ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(8 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(1 year, 4 months ago) | |
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(1 year, 4 months ago) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(3 years from now) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 4 months ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(6 months from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(3 years from now) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 16 days from now) | |
|
US8642760 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 months ago) | |
|
US8642600 (Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(10 months ago) | |
|
US8580796 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 months ago) | |
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(1 year, 6 months from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 07 June, 2006
Treatment: Treatment of major depressive disorder (mdd); Treatment of irritability associated with autistic disorder; Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia; Acute tr...
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY family patents
55
United States
36
China
17
Hong Kong
11
Canada
11
Japan
11
European Union
10
Poland
10
Norway
8
Spain
8
Denmark
8
Ukraine
8
Portugal
7
Argentina
7
Cyprus
6
Austria
6
Germany
6
Slovenia
5
Russia
5
Korea, Republic of
5
Taiwan
4
Israel
4
Georgia
3
Malaysia
3
Brazil
3
New Zealand
3
Peru
3
Mexico
3
Australia
3
Ecuador
3
South Africa
2
Lithuania
2
Hungary
1
Philippines
1
Singapore
1
Chile
1
Colombia
2. List of Abilify Mycite Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(8 months ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(8 months ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(8 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(1 year, 4 months ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 4 months ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(6 months from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(3 years from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(3 years from now) | |
| US8945005 | OTSUKA | Controlled activation ingestible identifier |
Aug, 2029
(6 years from now) | |
| US8956288 | OTSUKA | In-body power source having high surface area electrode |
Jul, 2029
(6 years from now) | |
| US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(7 years from now) | |
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(10 years from now) | |
| US8674825 | OTSUKA | Pharma-informatics system |
Apr, 2029
(5 years from now) | |
| US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(6 years from now) | |
| US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(4 years from now) | |
| US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(6 years from now) | |
| US9433371 | OTSUKA | In-body device with virtual dipole signal amplification |
Sep, 2029
(6 years from now) | |
| US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(7 years from now) | |
| US11229378 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(8 years from now) | |
| US9320455 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(8 years from now) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 16 days from now) | |
| US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(5 years from now) | |
| US9258035 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(5 years from now) | |
| US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(7 years from now) | |
| US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(7 years from now) | |
| US7978064 | OTSUKA | Communication system with partial power source |
Sep, 2026
(3 years from now) | |
| US8718193 | OTSUKA | Active signal processing personal health signal receivers |
Dec, 2029
(6 years from now) | |
| US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(7 years from now) | |
| US9060708 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(5 years from now) | |
| US9149577 | OTSUKA | Body-associated receiver and method |
Dec, 2029
(6 years from now) | |
| US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(9 years from now) | |
| US10441194 | OTSUKA | Ingestible event marker systems |
Jul, 2029
(6 years from now) | |
| US11476952 | OTSUKA | Pharma-informatics system |
Apr, 2026
(2 years from now) | |
| US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(7 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia; Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a tablet embedded w...
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
219
United States
61
Japan
58
China
46
European Union
34
Canada
32
Israel
30
Hong Kong
26
Korea, Republic of
26
Taiwan
18
Denmark
18
Australia
17
Spain
14
Malaysia
14
Brazil
14
Singapore
13
Ukraine
12
Portugal
12
Mexico
11
Poland
11
Russia
11
South Africa
10
Norway
8
Cyprus
7
Argentina
7
Slovenia
6
Austria
6
Germany
5
New Zealand
4
India
4
Peru
4
Georgia
4
Ecuador
3
Chile
2
Philippines
2
Lithuania
2
Hungary
1
Morocco
1
EA
1
Costa Rica
1
Finland
1
Colombia
1
Tunisia
3. List of Addyi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7420057 | SPROUT PHARMS | Stable polymorph of flibanserin |
Aug, 2022
(9 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8227471 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
May, 2023
(22 days ago) | |
| US9468639 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
Oct, 2022
(7 months ago) | |
| US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(4 years from now) | |
Drugs and Companies using FLIBANSERIN ingredient
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET;ORAL
ADDYI family patents
23
United States
10
European Union
5
China
4
Brazil
4
Argentina
4
Japan
4
Korea, Republic of
2
Spain
2
Austria
2
Malaysia
2
Denmark
2
Germany
2
Poland
2
Yugoslavia
2
Canada
2
Ukraine
2
EA
2
Norway
2
New Zealand
2
Croatia
2
Israel
2
Portugal
2
Mexico
2
Australia
2
Ecuador
2
South Africa
2
Slovenia
2
Hungary
1
Hong Kong
1
ME
1
Colombia
4. List of Amlodipine Besylate drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6828339 | SYNTHON PHARMS | Amlodipine salt forms and processes for preparing them |
Nov, 2022
(6 months ago) | |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 27 September, 2007
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
AMLODIPINE BESYLATE family patents
3
United States
1
Netherlands
1
Argentina
1
Norway
1
Australia
1
European Union
5. List of Banzel drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6740669 | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Nov, 2022
(6 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6740669 (Pediatric) | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
May, 2023
(17 days ago) | |
Drugs and Companies using RUFINAMIDE ingredient
Market Authorisation Date: 14 November, 2008
Treatment: NA
Dosage: TABLET;ORAL
6. List of Beyaz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6441168 | BAYER HLTHCARE | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Jul, 2022
(10 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Mar, 2022
(1 year, 2 months ago) | |
| US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(6 years from now) | |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 24 September, 2010
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
BEYAZ family patents
8
United States
3
Korea, Republic of
3
Australia
3
European Union
2
Spain
2
Denmark
2
Czech Republic
2
China
2
Canada
2
EA
2
Japan
2
ME
2
Croatia
2
Israel
2
Slovenia
2
Hungary
1
Uruguay
1
IB
1
Hong Kong
1
Austria
1
RS
1
Germany
1
Poland
1
Yugoslavia
1
Brazil
1
Estonia
1
Ukraine
1
Argentina
1
Norway
1
New Zealand
1
Cyprus
1
Peru
1
Portugal
1
Taiwan
1
Mexico
1
Bulgaria
1
South Africa
1
Slovakia
1
Lithuania
7. List of Caprelsa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE42353 | GENZYME CORP | Quinazoline derivatives and pharmaceutical compositions containing them |
Jun, 2022
(11 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642608 | GENZYME CORP | Quinazoline derivatives as VEGF inhibitors |
Feb, 2022
(1 year, 3 months ago) | |
| US8067427 | GENZYME CORP | Pharmaceutical compositions comprising ZD6474 |
Aug, 2028
(5 years from now) | |
Drugs and Companies using VANDETANIB ingredient
Market Authorisation Date: 06 April, 2011
Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease
Dosage: TABLET;ORAL
CAPRELSA family patents
10
United States
5
European Union
4
Korea, Republic of
3
Spain
3
Austria
3
Hong Kong
3
Denmark
3
Germany
3
China
3
United Kingdom
3
Brazil
3
Argentina
3
Norway
3
Portugal
3
Slovenia
2
Iceland
2
Poland
2
Russia
2
Canada
2
Ukraine
2
Japan
2
ME
2
New Zealand
2
Cyprus
2
Israel
2
Taiwan
2
Mexico
2
Australia
2
South Africa
1
Uruguay
1
Malaysia
1
Czech Republic
1
RS
1
Estonia
1
Croatia
1
Belgium
1
Bulgaria
1
Slovakia
1
Saudi Arabia
1
Luxembourg
1
Hungary
8. List of Chantix drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(9 months ago) | |
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(1 year, 25 days ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6890927 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(6 months ago) | |
|
US7265119 (Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(3 months ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Feb 22, 2022 |
| Pediatric Exclusivity (PED) | Aug 22, 2022 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL
CHANTIX family patents
3
United States
2
Ecuador
1
Panama
1
IB
1
Spain
1
Austria
1
Hong Kong
1
Dominican Republic
1
Malaysia
1
Iceland
1
Denmark
1
AP
1
Czech Republic
1
Germany
1
Poland
1
China
1
Yugoslavia
1
Brazil
1
Canada
1
Ukraine
1
Estonia
1
Morocco
1
Argentina
1
EA
1
Norway
1
OA
1
Japan
1
ME
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Guatemala
1
Peru
1
Israel
1
Portugal
1
Taiwan
1
Georgia
1
Mexico
1
Australia
1
Costa Rica
1
Bulgaria
1
South Africa
1
Slovakia
1
Egypt
1
Tunisia
1
Slovenia
1
Hungary
1
European Union
9. List of Combigan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7642258 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320976 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| US8133890 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| US9770453 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| US9907801 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| US8354409 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| US8748425 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| US9907802 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| US9474751 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| US7030149 | ALLERGAN | Combination of brimonidine timolol for topical ophthalmic use |
Apr, 2022
(1 year, 1 month ago) | |
| US7323463 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Jan, 2023
(4 months ago) | |
Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient
Market Authorisation Date: 30 October, 2007
Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of ...
Dosage: SOLUTION/DROPS;OPHTHALMIC
COMBIGAN family patents
21
United States
4
European Union
3
China
2
Mexico
1
Spain
1
Hong Kong
1
Denmark
1
Brazil
1
Canada
1
Norway
1
Japan
1
New Zealand
1
Korea, Republic of
1
Cyprus
1
Portugal
1
Taiwan
1
Australia
1
Ecuador
1
Slovenia
10. List of Dexilant drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(3 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(6 years from now) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(4 months from now) | |
| US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(8 years from now) | |
| US8722084 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(4 months from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(2 years from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(3 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(3 years from now) | |
|
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(10 months from now) | |
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(a month from now) | |
|
US7790755 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(3 years from now) | |
|
US8105626 (Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(3 years from now) | |
|
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(7 years from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(3 years from now) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(10 months from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive ...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
35
United States
23
Japan
12
European Union
9
Korea, Republic of
8
Canada
7
Spain
7
Argentina
6
China
5
Denmark
5
Brazil
5
Cyprus
5
Portugal
5
Australia
4
Hong Kong
4
Malaysia
4
Taiwan
4
Mexico
3
Poland
3
Russia
3
Norway
3
New Zealand
3
Peru
3
Israel
3
Costa Rica
2
Singapore
2
South Africa
2
Slovenia
1
Austria
1
Germany
1
Morocco
1
OA
1
Belgium
1
Chile
1
Colombia
1
Hungary
11. List of Dexilant Solutab drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(3 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(4 months from now) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(10 months from now) | |
|
US8871273 (Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(5 years from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(2 years from now) | |
| US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(5 years from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(a month from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(3 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB family patents
30
United States
21
Japan
10
European Union
8
Argentina
7
Canada
7
Korea, Republic of
5
Spain
5
China
5
Brazil
5
Peru
5
Taiwan
5
Australia
4
Malaysia
4
New Zealand
4
Mexico
4
Costa Rica
3
Hong Kong
3
Denmark
3
Poland
3
Norway
3
Cyprus
3
Portugal
3
South Africa
2
Morocco
2
Chile
2
Israel
2
Slovenia
1
Uruguay
1
Austria
1
Dominican Republic
1
Germany
1
Ukraine
1
Singapore
1
EA
1
OA
1
Belgium
1
Georgia
1
Ecuador
1
Colombia
1
Tunisia
1
Hungary
12. List of Folotyn drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6028071 | ACROTECH | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
Jul, 2022
(10 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8299078 | ACROTECH | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(2 years from now) | |
| US7622470 | ACROTECH | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(2 years from now) | |
Drugs and Companies using PRALATREXATE ingredient
Market Authorisation Date: 24 September, 2009
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma
Dosage: SOLUTION;INTRAVENOUS
FOLOTYN family patents
12
United States
2
China
2
New Zealand
2
Korea, Republic of
1
Spain
1
Hong Kong
1
Austria
1
Denmark
1
RS
1
Germany
1
Poland
1
Brazil
1
Canada
1
Norway
1
Japan
1
ME
1
Croatia
1
Portugal
1
Mexico
1
Australia
1
South Africa
1
Slovenia
1
European Union
13. List of Fusilev drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6500829 | ACROTECH | Substantially pure diastereoisomers of tetrahydrofolate derivatives |
Mar, 2022
(1 year, 2 months ago) | |
Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient
Market Authorisation Date: 07 March, 2008
Treatment: NA
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
14. List of Lexapro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6916941 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(9 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7420069 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(9 months ago) | |
|
US6916941 (Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(3 months ago) | |
|
US7420069 (Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(3 months ago) | |
Drugs and Companies using ESCITALOPRAM OXALATE ingredient
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
LEXAPRO family patents
4
Denmark
4
Japan
3
United States
2
Spain
2
Austria
2
Germany
2
China
2
Croatia
2
Portugal
2
European Union
1
Uruguay
1
Hong Kong
1
Malaysia
1
Turkey
1
Iceland
1
Poland
1
Yugoslavia
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
Argentina
1
EA
1
Norway
1
ME
1
New Zealand
1
Korea, Republic of
1
Peru
1
Israel
1
Mexico
1
Australia
1
Bulgaria
1
South Africa
1
Colombia
1
Egypt
1
Tunisia
1
Slovenia
1
Hungary
15. List of Lusedra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6204257 | EISAI INC | Water soluble prodrugs of hindered alcohols |
Jul, 2022
(10 months ago) | |
Drugs and Companies using FOSPROPOFOL DISODIUM ingredient
Market Authorisation Date: 12 December, 2008
Treatment: Sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation
Dosage: SOLUTION;INTRAVENOUS
16. List of Macrilen drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6861409 | NOVO | Growth hormone secretagogues |
Aug, 2022
(9 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192719 | NOVO | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 20, 2024 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION;ORAL
MACRILEN family patents
5
United States
5
European Union
4
Spain
4
Denmark
3
Austria
3
Hong Kong
3
Germany
3
Japan
3
Cyprus
3
Portugal
3
Bulgaria
2
Czech Republic
2
Poland
2
China
2
Taiwan
2
Australia
2
United Kingdom
1
Russia
1
Brazil
1
Canada
1
Ukraine
1
Argentina
1
Norway
1
New Zealand
1
Korea, Republic of
1
Israel
1
Slovenia
1
Mexico
1
Netherlands
1
South Africa
1
Slovakia
1
Hungary
17. List of Saxenda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(9 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(1 year, 5 months from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
|
US9968659 (Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| US8846618 | NOVO | Stable formulation of modified GLP-1 |
Jun, 2022
(11 months ago) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(3 years from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(11 months from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(13 years from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(8 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(4 years from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 4 months ago) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(29 days from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 4 months ago) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(3 years from now) | |
|
US8920383 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(3 years from now) | |
|
US8846618 (Pediatric) | NOVO | Stable formulation of modified GLP-1 |
Dec, 2022
(5 months ago) | |
|
USRE46363 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(3 years from now) | |
|
US9457154 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(4 years from now) | |
|
US9687611 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(4 years from now) | |
|
US9861757 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(3 years from now) | |
|
US9616180 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(3 years from now) | |
|
US9775953 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(3 years from now) | |
|
US9108002 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(3 years from now) | |
|
US9132239 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(9 years from now) | |
|
US9486588 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(10 months ago) | |
|
US6268343 (Pediatric) | NOVO | Derivatives of GLP-1 analogs |
Feb, 2023
(3 months ago) | |
|
US8672898 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(10 months ago) | |
|
US8114833 (Pediatric) | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(2 years from now) | |
|
US6899699 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(10 months ago) | |
|
US8684969 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(2 years from now) | |
|
US8579869 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(6 months from now) | |
|
US10220155 (Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(3 years from now) | |
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 4, 2023 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity
Dosage: SOLUTION;SUBCUTANEOUS
SAXENDA family patents
57
United States
28
Denmark
28
European Union
15
Japan
13
Spain
13
China
10
Poland
9
Australia
8
Russia
8
Canada
7
Austria
7
Germany
6
Brazil
6
Portugal
3
Korea, Republic of
3
Slovenia
3
Hungary
2
Mexico
2
South Africa
1
Hong Kong
1
Philippines
1
Turkey
1
RS
1
Morocco
1
Croatia
1
Cyprus
1
Israel
1
Chile
18. List of Teflaro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6417175 | ALLERGAN | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Apr, 2022
(1 year, 1 month ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8247400 | ALLERGAN | Cephem compounds useful for the treatment of bacterial infections |
Feb, 2031
(7 years from now) | |
| US9629861 | ALLERGAN | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Sep 13, 2022 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Method of treating bacterial infections; Methods for treating bacterial infections
Dosage: POWDER;INTRAVENOUS
TEFLARO family patents
8
United States
3
New Zealand
2
Canada
2
Peru
2
Mexico
1
Dominican Republic
1
China
1
Brazil
1
Ukraine
1
Singapore
1
EA
1
Nicaragua
1
Honduras
1
Korea, Republic of
1
Guatemala
1
Chile
1
Australia
1
Cuba
1
Costa Rica
1
Ecuador
1
South Africa
1
Colombia
1
European Union
19. List of Toviaz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(10 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
|
US6858650 (Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(4 months ago) | |
|
US7807715 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
|
US8088398 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
|
US8501723 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Jun 17, 2024 |
| Pediatric Exclusivity (PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
TOVIAZ family patents
6
United States
20. List of Velcade drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6958319 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(1 year, 4 months ago) | |
| US6713446 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(1 year, 4 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6713446 (Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(10 months ago) | |
|
US6958319 (Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(10 months ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Apr 8, 2022 |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 13 May, 2003
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
VELCADE family patents
9
United States
4
European Union
3
Spain
3
Cyprus
3
Denmark
2
Canada
2
Portugal
2
Japan
1
Germany
1
Hong Kong
1
Austria
1
Turkey
1
Australia
21. List of Venlafaxine Besylate drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6717015 | ALMATICA | Venlafaxine besylate |
Mar, 2023
(2 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(4 years from now) | |
Drugs and Companies using VENLAFAXINE BESYLATE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Treatment of depression and generalized anxiety disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE BESYLATE family patents
4
United States
2
European Union
1
South Africa
1
Argentina
1
Australia
22. List of Viibryd drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7834020 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(11 months ago) | |
| US8673921 | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(11 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236804 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun, 2022
(11 months ago) | |
| US8193195 | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(11 months ago) | |
|
US7834020 (Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(5 months ago) | |
|
US8193195 (Pediatric) | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(5 months ago) | |
|
US8236804 (Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(5 months ago) | |
|
US8673921 (Pediatric) | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(5 months ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jan 31, 2023 |
| Pediatric Exclusivity (PED) | Jul 31, 2023 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 January, 2011
Treatment: Treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
VIIBRYD family patents
16
Canada
15
United States
3
Japan
3
European Union
2
Hong Kong
2
Czech Republic
2
China
2
Slovakia
1
Spain
1
Austria
1
Malaysia
1
Denmark
1
Germany
1
Poland
1
Russia
1
Brazil
1
Estonia
1
Ukraine
1
Argentina
1
New Zealand
1
Korea, Republic of
1
Cyprus
1
Israel
1
Portugal
1
Mexico
1
Australia
1
Ecuador
1
South Africa
1
Hungary
23. List of Vimpat drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(1 year, 2 months ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Nov 16, 2023 |
| New Patient Population (NPP) | Oct 14, 2024 |
Drugs and Companies using LACOSAMIDE ingredient
Market Authorisation Date: 28 October, 2008
Treatment: Method of treating partial onset seizures in patients 4 years of age and older; Method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient w...
Dosage: SOLUTION;INTRAVENOUS
24. List of Vyvanse drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(3 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7659254 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7671030 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7723305 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7718619 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7662788 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7713936 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7678771 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7678770 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7674774 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7687467 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7105486 | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Feb, 2023
(3 months ago) | |
| US7671031 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7223735 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(3 months ago) | |
| US7700561 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
| US7687466 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(3 months ago) | |
|
US7718619 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 months from now) | |
|
US7223735 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(2 months from now) | |
|
US7655630 (Pediatric) | ||||